My mom is has NSCLC Stage IV, EGFR+, and has developed resistance to Tarceva after quite a long run. Her oncologist is recommending the AP26113 trial. Do we have any evidence that this drug is beneficial to people such as my mom? It seems that this drug is intended for ALK+ patients? Anyone been on this trial or have any comments to add about side effects? Any information would be greatly appreciated. Many thanks in advance.
Sat, 07/13/2013 - 15:28#1
AP26113 Trial - 1257896